We found that the level of RAB32 was higher in CML samples than healthy samples, and it was significantly downregulated in patients after treatment with nilotinib or imatinib (Figures 5B, C). The gene discussed is RAB32; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.